Item 3.02 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or


          Standard; Transfer of Listing.

As previously disclosed on September 29, 2022, Aridis Pharmaceuticals, Inc. (the "Company") received written notice (the "Notice") from the Nasdaq Stock Market, LLC ("Nasdaq") indicating that the market value of its listed securities has been below the minimum $35,000,000 required for continued listing as set forth in Listing Rule 5550(b)(2) (the "Rule) for the previous 30 consecutive trading days. In accordance with Listing Rule 5810(c)(3)(C), the Company was provided 180 calendar days, or until March 28, 2023, to regain compliance with the Rule.

On March 29, 2023, Nasdaq informed the Company that it had not regained compliance with the Rule and that its securities will be delisted from The Nasdaq Capital Market on April 10, 2023, unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the "Panel"). The Company intends to request a hearing before the Panel, which request will stay any delisting action by Nasdaq at least pending the issuance of the Panel's decision following the hearing and the expiration of any extension period that may be granted by the Panel. At the hearing, the Company will present its plan to evidence compliance with the Rule and request an extension of time within which to do so.

The Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol "ARDS" at least pending the ultimate conclusion of the hearing process.

Item 5.02 Departure of Directors or Principal Officers; Election of Directors;


          Appointment of Principal Officers.

On March 27, 2023, Craig Gibbs resigned as a director of the Company for personal reasons.

-2-

© Edgar Online, source Glimpses